Professional
Added to YB: 2026-03-06
Pitch date: 2026-03-04
LOVE.V [bullish]
Cannara Biotech Inc.
Author Info
Atrium Research provides institutional quality research on underfollowed public equities. Sign up for the newsletter.
Company Info
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada.
Market Cap
CAD 181.8M
Pitch Price
N/A
Price Target
3.00
Dividend
N/A
EV/EBITDA
7.45
P/E
15.44
EV/Sales
1.78
Sector
Personal Care Products
Category
growth
Cannara Biotech – Scalable Facilities, Record Profitability, and Re-Rating Potential
LOVE.V: Quebec-based LP w/ 100k kg capacity, 111% revenue CAGR since 2020, 4.4% Canada market share (Dec'25), #1 in QC. Best-in-class 29% adj EBITDA margin vs 9% peer avg, 45% gross margin from low QC electricity rates. Purpose-built $250M Valleyfield facility bought for $33M; 12 of 24 zones active, each zone adds $10-13M rev at minimal capex. Vape launch in QC Nov'25 captured 30% share. 19 consecutive qtrs adj EBITDA+, 6% annualized dilution (vs peer avg 29%). Trades 6.5x FY26E EBITDA vs large-cap 7.4x despite superior growth/margins. $30M 3yr capex plan, 17% FY26E/16% FY27E rev growth. PT $3 (10x FY26E EBITDA), 63% upside.
Read full article (25 min)